DFW

DOCKET NO.: WYNC-0714 (AM101222 L1) **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Darlene C. Deecher et al. **Confirmation No.: 7110**

Application No.: 10/685,974 **Group Art Unit: 1632**

Filing Date: October 14, 2003 **Examiner: Not yet known**

For: Novel Method of Treating Vasomotor Symptoms

DATE OF DEPOSIT: May 20, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450. Heather Kite

TYPED NAME: Heather Kite

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of **$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **$180.00** as set forth in § 1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☒ Copies of references **42-48** listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

☒ In view of the voluminous nature of references **40 and 41**, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§ 120 have been made in the instant application:

☐ Copies of references **[list as appropriate]** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. , filed .

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the corresponding PCT/US03/32554 Search Report dated February 26, 2004.

There are no listed references which are not in the English language.

Date: May 20, 2004

Wendy A. Choi
Registration No. 36,697

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2004 WW

OIPE
MAY 24 2004
PATENT & TRADEMARK OFFICE
JC53

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. WYNC-0714/ (AM101222 L1)	Application No. 10/685,974
	Applicant Darlene C. Deecher et al.	
	Filing Date October 14, 2003	Group 1632
	Confirmation No. 7110	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Clinical Trial: "Phase III Randomized Study of Medroxyprogesterone Versus Venlafaxine in Women With Symptomatic Hot Flashes", www.clinicaltrials.gov sponsored by the National Institutes of Health, Study ID Numbers: CDR0000069217; NCCTG-N99C7; NCI-P02-0204, **2003**, 6 pages
	2	Acs, N. et al., "Estrogen improves impaired musculocutaneous vascular adrenergic reactivity in pharmacologically ovariectomized rats: a potential peripheral mechanism for hot flashes?", *Endocrinology,* **2001** 15: 68-73
	3	Barlow, D. H., "Venlafaxine for hot flushes," *Lancet*, **16 December 2000**, 356(9247): 2025-2026
	4	Barton, D. et al., "Hot Flashes – Aetiology and Management," *Drugs and Aging*, **2001**, 18(8): 597-606
	5	Berendsen, H. H. G., "Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats," *European Journal of Pharmacology*, **2001**, 419(1): 47-54
	6	Berendsen, H. H. G., "The role of serotonin in hot flushes," *Maturitas*, **2000**, 36(3): 155-164
	7	Berendsen, H. H. G., "Hot Flushes and serotonin," *Journal of the British Menopause Society*, **March 2002**, 8(1): 30-34
	8	Bundgaard, H., "Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs," *Advanced Drug Deliver Reviews*, **1992**, 8, 1-38
	9	Bundgaard, H. et al., "Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties," *J. of Pharmaceutical Sciences*, **April 1988**, 77(4):285
	10	Casper, R. F. et al., "Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism," *Clinical Endocrinology*, **1985**, 22: 293-312
	11	Fink, G. et al., "Oestrogen and mental state," *Nature*, **1996**, 383(6598): 306
	12	Freedman, R. R., "Physiology of hot flashes," *American Journal of Human Biology*, **2001**, 13: 453-464
	13	Freedman, R. R. et al., "Clonidine raises the sweating threshold in symptomatic but not asymptomatic postmenopausal women," *Fertility & Sterility*, **2000**, 74(1): 20-3
	14	French, N., "α_2-Adrenoceptors and I_2 sites in the mammalian central nervous system," *Pharmacol. Ther.*, **1995**, 68(2):175-208

EXAMINER	**DATE CONSIDERED**

© 2004 WW

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. WYNC-0714/ (AM101222 L1)	Application No. 10/685,974
	Applicant Darlene C. Deecher et al.	
	Filing Date October 14, 2003	Group 1632
	Confirmation No. 7110	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	15	Janowsky, et al., "Desipramine: an overview," *Journal of Clinical Psychiatry*, **1984**, 45(10 Pt 2): 3-9
	16	Katovich, M. J. et al., "Mechanisms mediating the thermal response to morphine withdrawal in rats," *Proceedings of the Society for Experimental Biology & Medicine*, **1990**, 193(2): 129-35
	17	Katovich, M. J. et al., "Alpha-adrenergic mediation of the tail skin temperature response to naloxone in morphine-dependent rats," *Brain Research*, **1987**, 426: 55-61
	18	Kramer et al., In: Murphy *et al.*, *3rd Int'l Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment-Proceedings*, Paris, France: SCI: 3-7 **1992**
	19	Kronenberg et al., "Thermoregulatory Physiology of Menopausal Hot Flashes: A Review," *Can. J. Physiol. Pharmacol.*, **1987**, 65:1312-1324
	20	Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191, **1991**
	21	Loprinzi, C. L., et al., "Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial," *Lancet*, **2000**, 356(9247): 2059-2063
	22	Loprinizi, C. L. et al. "Pilot Evaluation of Venlafaxine Hydrochloride for the Therapy of Hot Flashes in Cancer Survivors," *Journal of Clinical Oncology*, **July 1998**, 16(7): 2377-2381
	23	Mackinnon et al., "α_2-Adrenoceptors: more subtypes but fewer functional differences," *TIPS*, **1994**, 15: 119-123
	24	Merchenthaler et al., "The effect of estrogens and antiestrogens in a rat model for hot flush," *Maturitas*, **1998**, 30(3): 307-316
	25	Morin, S. M., "Atomoxetine Selectively Induces Fos Expression in the Rat Prefrontal Cortex," Presented at Society for Neuroscience Annual Meeting (SFN); **November 2-7, 2002**, Orlando, FL
	26	Pacholczyk, T. et al., "Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter," *Nature*, **1991**, 350(6316): 350-4
	27	Panek, D.U. et al., "Effect of continuous intraventricular estrogen or catechol estrogen treatment on catecholamine turnover in various brain regions," *J. Pharmacol. Exp. Ther.*, **1986**, 236(3), 646-652

EXAMINER	**DATE CONSIDERED**

© 2004 WW

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. WYNC-0714/ (AM101222 L1)	Application No. 10/685,974
	Applicant Darlene C. Deecher et al.	
	Filing Date October 14, 2003	Group 1632
	Confirmation No. 7110	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	28	Prasad, P.D., et al., "Functional expression of the plasma membrane serotonin transporter but not the vesicular monoamine transporter in human placental trophoblasts and choriocarcinoma cells," Placenta, **1996**, 17(4): 201-7
	29	Quella, S. K. et al., "Pilot evaluation of Venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer," *The Journal of Urology*, **July 1999**, 162: 98-102
	30	Reneric, J-Ph. et al., "Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test," *Nueropsychopharmacology*, **April 2001**, 24(4): 379-390
	31	Rosenberg, J. et al., "Hypothesis: pathogenesis of postmenopausal hot flush," *Medical Hypotheses*, **1991**, 35: 349-350
	32	Shaw, C. R., "The perimenopausal hot flash: epidemiology, physiology, and treatment," *Nurse Practitioner*, **1997**, 22: 55-56, 61-66
	33	Stearns, V. et al., "Hot flushes," *Lancet*, **December 7, 2002**, 360(9348): 1851-1861
	34	Stearns,V. et al., "Paroxetine controlled release in the treatment of menopausal hot flashes," *JAMA*, **2003**, 289:2827-2834
	35	Stearns,V. et al., "A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors," *Ann Oncol.*, **2000**,11:17-22
	36	Waldinger et al., "Treatment of hot flushes with mirtazapine: four case reports," *Maturitas*, **2000**, 36(3): 165-168
	37	Wilen, S.H. *Tables of Resolving Agents and Optical Resolutions*, pp. 268-298, E.L. Eliel, Ed., University of Notre Dame Press, Notre Dame, IN **1972**
	38	Wilen, S.H., et al., "Strategies in optical resolutions," *Tetrahedron*, 33:2725, **1977**
	39	Zhang, W. et al., "Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex," *Neuropsychopharmacology*, **2000**, 23(3): 250-262
*	**40**	*Remington's Pharmaceutical Sciences*, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA 1985
*	**41**	Hand Book of Pharmaceutical Excipients, second edition, American Pharmaceutical Association, 1994

EXAMINER	**DATE CONSIDERED**

*A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and may be obtainable by the Examiner.

© 2004 WW

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. WYNC-0714/ (AM101222 L1)	Application No. 10/685,974
	Applicant Darlene C. Deecher et al.	
	Filing Date October 14, 2003	Group 1632
	Confirmation No. 7110	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES	Translation NO
	58	91/18602 A1	12/12/91	WO		
	59	99/44601 A1	09/10/99	WO		
	60	03/037334 A1	05/08/03	WO		
	61	03/077897 A1	09/25/03	WO		
	62	2004/016272 A1	02/26/04	WO		
	63	02/064543 A1	08/22/02	WO		
	64	02/078691 A1	10/10/02	WO		
	65	0 208 235 B1	01/10/90	EP		
	66	1 266 659 A1	12/18/02	EP		
	67	0 303 961 A1	02/22/89	EP		
	68	0 065 757 A1	12/01/82	EP		

EXAMINER	**DATE CONSIDERED**

© 2004 WW

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. WYNC-0714/ (AM101222 L1)	Application No. 10/685,974
	Applicant Darlene C. Deecher et al.	
	Filing Date October 14, 2003	Group 1632
	Confirmation No. 7110	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	42	3,454,554	07/08/69	Biel et al.	260	239
	43	4,310,524	01/12/82	Wiech et al.	514	217
	44	4,535,186	08/13/85	Husbands et al.	564	336
	45	4,826,844	05/02/89	Husbands et al.	514	252
	46	5,502,047	03/26/96	Kavey	514	183
	47	2002/0107249 A1	08/08/02	Wong et al.	514	238.5
	48	2002/0128173 A1	09/12/02	Wong et al.	514	1
	49	10/684,777	10/14/03	Deecher et al.		
	50	10/685,812	10/14/03	Deecher et al.		
	51	60/511,542	10/14/03	Mahaney et al.		
	52	60/511,042	10/14/03	Mahaney et al.		
	53	60/511,002	10/14/03	Mahaney		
	54	60/510,811	10/14/03	Trybulski et al.		
	55	60/510,943	10/14/03	Trybulski et al.		
	56	60/511,001	10/14/03	Mahaney et al.		
	57	60/510,942	10/14/03	Trybulski et al.		

EXAMINER	**DATE CONSIDERED**

© 2004 WW